<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25E8481C-10ED-461A-931E-4C9F58F89CC8"><gtr:id>25E8481C-10ED-461A-931E-4C9F58F89CC8</gtr:id><gtr:name>Topigen Pharmaceuticals Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D84524C1-A84E-4BEB-A4B1-AB63D2D10B66"><gtr:id>D84524C1-A84E-4BEB-A4B1-AB63D2D10B66</gtr:id><gtr:name>StormBio</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25E8481C-10ED-461A-931E-4C9F58F89CC8"><gtr:id>25E8481C-10ED-461A-931E-4C9F58F89CC8</gtr:id><gtr:name>Topigen Pharmaceuticals Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D84524C1-A84E-4BEB-A4B1-AB63D2D10B66"><gtr:id>D84524C1-A84E-4BEB-A4B1-AB63D2D10B66</gtr:id><gtr:name>StormBio</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4608E704-6475-4CCA-AD08-F356E4757A3D"><gtr:id>4608E704-6475-4CCA-AD08-F356E4757A3D</gtr:id><gtr:firstName>Tracy</gtr:firstName><gtr:surname>Hussell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400795"><gtr:id>2DFCA4DE-C979-43D1-A68D-5B1AE3DF4FFB</gtr:id><gtr:title>Innate priming and the immunopathogenesis of lung co-infections</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400795</gtr:grantReference><gtr:abstractText>We all suffer from respiratory infections. In those most fortunate the infection is restricted to the nasal passages. However, in a significant proportion of children less than one year of age, elderly patients, those with a deficient immune system and even healthy adults, respiratory infections kill. According to the World Health Organisation respiratory infections are the third leading cause of death and disability worldwide and yet vaccines do not exist for even the most prominent pathogens. Attempts to understand mechanisms of disease are vital for the rational development of new therapeutics. 

We have previously reported that neutralization of inflammatory mediators or removal of specific cell subsets, prevent illness during respiratory infection. Inhibition of ?OX40? expressed by immune cells received wide publicity on television and radio stations and in news papers. We have also documented the impact that one lung infection has on subsequent unrelated pathogens at the same site. Remarkably, previous exposure to influenza virus modulates immunity to respiratory syncytial virus. Similarly, lung BCG infection prevents allergic responses to fungal pathogens. Public understanding of scientific advances is vital for the momentum that drives these ideas into the clinic. As science develops novel concepts evolve that need to be tested in biological systems. 

Preliminary data highlights several novel and exciting areas that have never been tested in the setting of respiratory infections. For example, cells that are stressed (by infection, trauma or oxygen starvation) produce a ?retaliatory metabolite?, adenosine that we believe plays a critical role in the outcome of respiratory infection. Additionally, the body senses the presence of an invader using receptors that recognize shapes or patterns on the virus or bacterial surface. The role of these ?pattern recognition receptors? in respiratory defense is not known but investigated in this application. Finally, humans are never free of previous or concurrent infections. Simultaneous lung infections are the norm rather than the exception and yet have received relatively little attention. Studies performed during influenza pandemics for example, show that the incidence of associated bacterial pneumonia ranged from 2-18% depending on the population studied. We will study the interaction between 4 common respiratory pathogens.

These studies will directly influence the development of future therapeutics or vaccines and therefore drastically improve the quality of life and how health care is delivered to those most affected. Such improvement in public health impacts on the distribution of resources within an already stretched national health service.</gtr:abstractText><gtr:technicalSummary>Respiratory infections are the third leading cause of death worldwide and yet vaccines are not available for those most prevalent. Insights into the pathogenesis of lung infectious diseases are therefore vital for rational vaccine development. Previous MRC funding allowed us to develop novel themes and therapeutics to combat prominent respiratory pathogens. The unifying feature of our studies is that detrimental lung immunopathology is inhibited when the inflammatory infiltrate in the lung is reduced: for example by inhibiting inflammatory cytokines, by depletion of specific cell subsets or by inhibiting novel molecules such as OX40, which reduces the number of recently activated T cells. We have also determined that previous lung infection inhibits immunopathology to a subsequent unrelated lung pathogen, again by reducing the inflammatory infiltrate or by modifying the immune response to a phenotype more capable of eliminating the second pathogen. For example, lung influenza virus prevents immunopathology to respiratory syncytial virus (RSV) and BCG prevents lung eosinophilic pathology to Cryptococcus neoformans. This effect is long lasting and does not rely on T or B lymphocytes. The lung microenvironment is therefore ?imprinted?, perhaps permanently by the first infection but the precise mechanisms remain unclear and will be addressed as follows in the current proposal.

1) One lung infection modulates immunity and pathology to a second unrelated pathogen. The present application is a proposal to study the mechanisms responsible for imprinting the lung microenvironment before the second infection. In particular, preliminary evidence implicates an interactive role for adenosine and Toll-like receptors.
2) Humans are rarely infected with a single pathogen. Specimens retrieved from post mortem lung taken from those that died during influenza pandemics clearly show bacterial involvement. In this application we will investigate how lung influenza virus and Streptococcus pneumoniae or Haemophilus influenzae inter-relate and mechanisms that lead to heightened disease.

To address these questions we will use well established immune competent or gene deficient mouse models (or in vitro assays where possible) whilst collaborating with a variety of experts worldwide. The hypotheses proposed are novel with respect to lung immunology, topical and backed by strong preliminary data. The results of these investigations may yield significant insight into the immunopathogenesis of lung infectious disease, which will impact on human and animal health.</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>410053</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Topigen Pharmaceuticals Inc.</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>acute lung inflammation</gtr:description><gtr:id>C10FF6EB-94CD-493D-B333-6D70DFA3DC8A</gtr:id><gtr:impact>The research undertaken in this grant led to the development of a company called Stormbio</gtr:impact><gtr:outcomeId>3A190481197-2</gtr:outcomeId><gtr:partnerContribution>Access to reagents that are unavailable elsewhereProvision of reagents unavailable elsewhere</gtr:partnerContribution><gtr:piContribution>This company are developing strategies to alleviate acute lung inflammation. I consult for them in 3 hour teleconferences 4 times a year. It may lead to funding in my laboratory</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>StormBio</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>regulation of cytokine storm</gtr:description><gtr:id>10806AF2-0DA6-4581-AA2B-3E777C2663E7</gtr:id><gtr:impact>We have tested potential therapeutic reagents for a number of companies and are currently liaising with Cellgene on a novel project. Should these studies work then we will have a novel therpaeutic for consideration in pandemic influenza infection that has already passed phase II trials in man</gtr:impact><gtr:outcomeId>545C00C5769-1</gtr:outcomeId><gtr:partnerContribution>this collaboration has put me in touch with other pharmaceutical companies</gtr:partnerContribution><gtr:piContribution>Based on my research record this company has been developed to identify strategies to prevent the cytokine storm during influenza infection and may open links with other industrial partners. I provide advise and technical expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Topigen Pharmaceuticals Inc.</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>acute lung inflammation</gtr:description><gtr:id>37B0ED7F-AB6E-471F-8AC0-0596EDEA9896</gtr:id><gtr:impact>The research undertaken in this grant led to the development of a company called Stormbio</gtr:impact><gtr:outcomeId>3A190481197-1</gtr:outcomeId><gtr:partnerContribution>Access to reagents that are unavailable elsewhereProvision of reagents unavailable elsewhere</gtr:partnerContribution><gtr:piContribution>This company are developing strategies to alleviate acute lung inflammation. I consult for them in 3 hour teleconferences 4 times a year. It may lead to funding in my laboratory</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIH funding</gtr:description><gtr:id>FE53621C-3785-43BB-A5B0-48D4E684C8E4</gtr:id><gtr:impact>MRC funding lead to NIH funding</gtr:impact><gtr:outcomeId>0C3FC8B7CEA-1</gtr:outcomeId><gtr:partnerContribution>Based on our concepts within the MRC grant we successfully co-applied for an NIH R01</gtr:partnerContribution><gtr:piContribution>Our concepts and data provided the basis for this whole application</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>809DBD60-FC4C-452C-AECC-56D7857720E8</gtr:id><gtr:impact>I regularly attend schools to speak with 6th form pupils and I'm on the biology for all website

Many school children have subsequently come to do work in my laboratory</gtr:impact><gtr:outcomeId>43C650FB296</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media release on published work</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A201334D-33B9-42DC-80DC-074A1208B0BD</gtr:id><gtr:impact>The work published in Nature Immunology was released by the MRC and Imperial press office, we gained recognition in a variety of newspapers and I was part of a documentary on Radion 4

This resulted in a number of press conferences</gtr:impact><gtr:outcomeId>4E1D5E98EDF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>careers workshop/education secretary</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C7E92A7A-ACF5-4AD0-8CDE-8B9EAB8E687F</gtr:id><gtr:impact>As education secretary and trustee of the British society for Immunology I run annual workshops at congress for school children

None</gtr:impact><gtr:outcomeId>AC51F92BE15</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bite sized Immunology</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8D8FF7EE-4D25-431B-B182-63778D15E9CA</gtr:id><gtr:impact>We have developed an online resource called bite-sized immunology targetted at school children

The site has been accessed 30,000 time since launch</gtr:impact><gtr:outcomeId>95850DFF9F2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0802353</gtr:fundingRef><gtr:id>8395B35A-75D2-476E-B140-FC0A05E8D04C</gtr:id><gtr:outcomeId>Mi1ZE5ASERw0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Henry Wellcome Fellowship</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E9B6FEA1-2197-405D-8534-2D842FD50D36</gtr:id><gtr:outcomeId>ciaARACuL770</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH RO1</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>NGA: 1 U01 AI070232-01</gtr:fundingRef><gtr:id>2BAA2300-B90C-4FFE-B68E-2EA0C58A62B9</gtr:id><gtr:outcomeId>D0CE86AB0480</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Centre for Respiratory Infection</gtr:department><gtr:description>Centre for respiratory infection infrastructure award</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9D51CC28-9C03-4051-8ED7-F4E887D9250D</gtr:id><gtr:outcomeId>BrFNkK57B530</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>093612/Z/10/Z</gtr:fundingRef><gtr:id>675C6370-CE0F-4566-825F-C6AD29BDE9F2</gtr:id><gtr:outcomeId>F64D854D8030</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have protected the use of mimetics to block reactive oxygen species during influenza infection as a strategy to alleviate clinical illness</gtr:description><gtr:grantRef>G0400795</gtr:grantRef><gtr:id>118882EF-0F20-4A0F-BF15-6BF0E83A7ADB</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>7AA2DF177DC</gtr:outcomeId><gtr:patentId>WO2008114017</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Mimetics to blocks ROS</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We identified that ligation of CD200R dampens innate inflammation during acute lung injury. The invention relates to therapeutic compositions for use in treating, ameliorating or preventing an infection such as a microbial infection in a subject, comprising a compound modulative of reactive oxygen species level, or CD200 level, or CD200R level, or a combination of two or more of said levels in said subject. The invention also relates to methods of treatment using such compositions. In addition, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing an inflammatory pulmonary infection in a mammalian host having a CD200-CD200R axis comprising a compound modulative of said axis, and to methods of treatment using such compositions.; Furthermore, the invention relates to therapeutic compositions for use in treating, ameliorating or preventing a microbial infection and/or pulmonary inflammation in a subject comprising a compound mimetic of superoxide dismutase, and to methods of treatment using such compositions.</gtr:description><gtr:grantRef>G0400795</gtr:grantRef><gtr:id>A0FEDEE7-1AF7-4312-B845-F903EAF57384</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>C1525A339A5</gtr:outcomeId><gtr:patentId>WO2009004339</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Blocakde of CD200R</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pandemic preparedness</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>256C4328-2E1A-427A-B710-C368F5ADA779</gtr:id><gtr:outcomeId>C4A1E1AF076</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>StormBio Inc</gtr:companyName><gtr:description>This is a fledgling company set up to test anti-inflammatory strategies for others.; www.stormbio.com</gtr:description><gtr:id>F81EA5BD-B7FA-4EF5-8B9C-EB393AE2B1C9</gtr:id><gtr:impact>The research has provided contacts with many companies in the feild of immune therapeutics</gtr:impact><gtr:outcomeId>6E4577460EC</gtr:outcomeId><gtr:url>http://www.stormbio.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>E687FEBE-AF77-4EE2-80EE-4B21F55D2000</gtr:id><gtr:title>An antiinflammatory role for IKKbeta through the inhibition of &amp;quot;classical&amp;quot; macrophage activation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29afe4c857eb3be13dc548e1b3af09f1"><gtr:id>29afe4c857eb3be13dc548e1b3af09f1</gtr:id><gtr:otherNames>Fong CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>DC4ED5CA2C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70698CBF-394D-440B-B1D9-B4B99F87339E</gtr:id><gtr:title>TGF-beta prevents eosinophilic lung disease but impairs pathogen clearance.</gtr:title><gtr:parentPublicationTitle>Microbes and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4caedb66bcfc1d4fcbe856af47164bdd"><gtr:id>4caedb66bcfc1d4fcbe856af47164bdd</gtr:id><gtr:otherNames>Williams AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1286-4579</gtr:issn><gtr:outcomeId>58ac458d095122.33722752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A5003A-0CFB-414F-8F02-9F3F828901FD</gtr:id><gtr:title>Role of CCL5 (RANTES) in viral lung disease.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9644b075595d5c3cd12806d2e790f714"><gtr:id>9644b075595d5c3cd12806d2e790f714</gtr:id><gtr:otherNames>Culley FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>186D689B929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DCFE9D3-8179-4939-9C40-80F1384CAC4E</gtr:id><gtr:title>The therapeutic potential of positive and negative immune cell co-stimulation during inflammation.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef3d632e12aee5de52cafea13213359b"><gtr:id>ef3d632e12aee5de52cafea13213359b</gtr:id><gtr:otherNames>Gwyer E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>5C41727B37F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BE54F05-4FAF-4ABE-934C-23028020E467</gtr:id><gtr:title>Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/228fd72efe361e1b94bed9eef6448a06"><gtr:id>228fd72efe361e1b94bed9eef6448a06</gtr:id><gtr:otherNames>Janot L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>E0EA50CDEFC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A31D850-8DDE-492B-BA9C-D167F2D0598B</gtr:id><gtr:title>The impact of successive infections on the lung microenvironment.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cb8ec275245ff6366bd9c09fa807bb2"><gtr:id>4cb8ec275245ff6366bd9c09fa807bb2</gtr:id><gtr:otherNames>Didierlaurent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>876EF1CB8CA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7007B92-C544-4106-B973-9BE07DDFCC98</gtr:id><gtr:title>Manipulation of acute inflammatory lung disease.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0ef9bd77dcd2684db8ee716a61e97eb"><gtr:id>d0ef9bd77dcd2684db8ee716a61e97eb</gtr:id><gtr:otherNames>Wissinger EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>F6192F594EC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4402759E-5499-477A-877D-331A4673B3AF</gtr:id><gtr:title>A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>s8pttVLoN1r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E082023-6393-42AE-A56E-EC77428BC3DC</gtr:id><gtr:title>Respiratory infections: do we ever recover?</gtr:title><gtr:parentPublicationTitle>Proceedings of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ad12f521963eb3602f7aeea5be777af"><gtr:id>0ad12f521963eb3602f7aeea5be777af</gtr:id><gtr:otherNames>Goulding J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1546-3222</gtr:issn><gtr:outcomeId>705625412FE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78576B85-D100-4997-90D4-4A53A1A790FE</gtr:id><gtr:title>Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c518375475dc60e989044f5c87a358c"><gtr:id>0c518375475dc60e989044f5c87a358c</gtr:id><gtr:otherNames>Thorpe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>B3A04553303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF130924-55D5-4B21-BD22-E6D3C1A27FE0</gtr:id><gtr:title>Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/854ceba29685db98d5f6eae1b410a101"><gtr:id>854ceba29685db98d5f6eae1b410a101</gtr:id><gtr:otherNames>Cosgrove CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5A6F8257DD2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB9FBB1E-F81D-4210-B18B-DFBBFFEA48A2</gtr:id><gtr:title>Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7906e4f7d7683a3ba88f3098b7e37385"><gtr:id>7906e4f7d7683a3ba88f3098b7e37385</gtr:id><gtr:otherNames>Edwards L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58ac458cde2b68.77895074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4B20EBC-FB40-4DC9-9148-1046A421FE79</gtr:id><gtr:title>Functional group/guild modelling of inter-specific pathogen interactions: a potential tool for predicting the consequences of co-infection.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f49a8c81802d1af971e2979864e0fc2"><gtr:id>7f49a8c81802d1af971e2979864e0fc2</gtr:id><gtr:otherNames>Lello J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>23012EDB929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF73C540-FC31-488F-BEEE-E19C8B3A3D24</gtr:id><gtr:title>In the Absence of Reactive Oxygen Species, T Cells Default to a Th1 Phenotype and Mediate Protection against Pulmonary Cryptococcus neoformans Infection</gtr:title><gtr:parentPublicationTitle>The Journal of Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a1a10011c7548cc1f957efe10cd92d5"><gtr:id>7a1a10011c7548cc1f957efe10cd92d5</gtr:id><gtr:otherNames>Snelgrove R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>5a6f09a893f084.39595988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F7D68BC-C468-49AF-9746-C12744D920C7</gtr:id><gtr:title>Themis2/ICB1 is a signaling scaffold that selectively regulates macrophage Toll-like receptor signaling and cytokine production.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1440ffabe03c4aa74bb80d0c63a09a3"><gtr:id>f1440ffabe03c4aa74bb80d0c63a09a3</gtr:id><gtr:otherNames>Peirce MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>PJ41sLhxTQF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9D0F58-B391-4DBF-A761-D4ED4DCEED03</gtr:id><gtr:title>In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>ECAE022F4DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>605BA60F-3B37-45B1-A21F-6918722B7894</gtr:id><gtr:title>Colonic bacterial infection abrogates eosinophilic pulmonary disease.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4caedb66bcfc1d4fcbe856af47164bdd"><gtr:id>4caedb66bcfc1d4fcbe856af47164bdd</gtr:id><gtr:otherNames>Williams AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>E47974E2754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE8BB015-2E81-4586-A024-66899FBFF552</gtr:id><gtr:title>Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?</gtr:title><gtr:parentPublicationTitle>Archivum immunologiae et therapiae experimentalis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecefa09d85814a49bb2cb0c90d926fed"><gtr:id>ecefa09d85814a49bb2cb0c90d926fed</gtr:id><gtr:otherNames>Cavanagh MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0004-069X</gtr:issn><gtr:outcomeId>E12BBC8BAD0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B885459D-C4EA-47EC-8246-B78F9C13F3AC</gtr:id><gtr:title>Immune homeostasis in the respiratory tract and its impact on heterologous infection.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31f779875d0c2b2940c32a8d78f82cc1"><gtr:id>31f779875d0c2b2940c32a8d78f82cc1</gtr:id><gtr:otherNames>Wissinger E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>A0251C169B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861293AA-E9F9-4334-BBB3-88E6535F561A</gtr:id><gtr:title>Structured regulation of inflammation during respiratory viral infection.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>CfXtULYtTEh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D5D236C-8124-4C22-83BF-484F7282D75C</gtr:id><gtr:title>Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9644b075595d5c3cd12806d2e790f714"><gtr:id>9644b075595d5c3cd12806d2e790f714</gtr:id><gtr:otherNames>Culley FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>2AFD1E7A113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2D0FBCA-BA68-4DFA-9D71-0BF6920F2199</gtr:id><gtr:title>Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51898115347a99ff6755c6b0c42b0390"><gtr:id>51898115347a99ff6755c6b0c42b0390</gtr:id><gtr:otherNames>Tourdot S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>A3BD5D8BA4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7D7AE5F-D5A0-4854-9508-ADD4926EBED4</gtr:id><gtr:title>The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>18C584AA1C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6004D5A2-A444-4444-B06B-692DF4F628AC</gtr:id><gtr:title>Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cb8ec275245ff6366bd9c09fa807bb2"><gtr:id>4cb8ec275245ff6366bd9c09fa807bb2</gtr:id><gtr:otherNames>Didierlaurent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>259BC0EC034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>996F1EDA-7610-4441-A4F0-BB549EBE3FE7</gtr:id><gtr:title>A critical function for CD200 in lung immune homeostasis and the severity of influenza infection.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>1D2F4E0F2DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37F8B80C-7CFA-49F1-93A5-3F8E125A6AD1</gtr:id><gtr:title>Bacterial complications during pandemic influenza infection.</gtr:title><gtr:parentPublicationTitle>Future microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86142b460f1cf0a7ecf7e1718361b611"><gtr:id>86142b460f1cf0a7ecf7e1718361b611</gtr:id><gtr:otherNames>Hussell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1746-0913</gtr:issn><gtr:outcomeId>A2DF77DBE17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D11C54D0-1030-4B6E-BB6B-F39B4ADBF28B</gtr:id><gtr:title>Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a224e0fe1b75053d9a217b647f359fc0"><gtr:id>a224e0fe1b75053d9a217b647f359fc0</gtr:id><gtr:otherNames>Drexler SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-9475</gtr:issn><gtr:outcomeId>ZQdgmamgBP6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A77CC995-9BCE-464F-BF01-7212150040B5</gtr:id><gtr:title>A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71c93b892436c62ab719df9f416a581"><gtr:id>b71c93b892436c62ab719df9f416a581</gtr:id><gtr:otherNames>Humphreys IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>DC799A6D168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52C312EE-3D0C-4A44-8EE8-65621C002B55</gtr:id><gtr:title>Sedation &amp;amp; immunomodulation.</gtr:title><gtr:parentPublicationTitle>Critical care clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2e5b1ee3098b90568bcaf68ba8fb2f9"><gtr:id>f2e5b1ee3098b90568bcaf68ba8fb2f9</gtr:id><gtr:otherNames>Sanders RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0749-0704</gtr:issn><gtr:outcomeId>153F9C2104F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7BAC50A-E3AE-4ED0-B874-E64A1431B0A2</gtr:id><gtr:title>The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/340b918fdc6c0b9b335905e583351264"><gtr:id>340b918fdc6c0b9b335905e583351264</gtr:id><gtr:otherNames>Tregoning JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>aba39Hy54Y8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC30654-0E58-47FC-B6FF-F5F6F57C3662</gtr:id><gtr:title>Amelioration of influenza-induced pathology in mice by coinfection with Trichinella spiralis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3672ea56223b077e49a54860f0c2b801"><gtr:id>3672ea56223b077e49a54860f0c2b801</gtr:id><gtr:otherNames>Furze RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>70AE7A3D81F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D10C3AD0-2E84-4E9B-8817-E546D763B655</gtr:id><gtr:title>Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3170c18542aa6f9fe7bfe8c17b6bb469"><gtr:id>3170c18542aa6f9fe7bfe8c17b6bb469</gtr:id><gtr:otherNames>Matthews SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58ac458cc192e1.15720467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D82BABA2-F0F9-452E-938D-3FC44B8E4397</gtr:id><gtr:title>Protection against tetanus toxin using a plant-based vaccine.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/340b918fdc6c0b9b335905e583351264"><gtr:id>340b918fdc6c0b9b335905e583351264</gtr:id><gtr:otherNames>Tregoning JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58ac458c9e0a24.93968232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6151725A-3BEA-414F-9860-16910171FCD5</gtr:id><gtr:title>The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b27cebc04fe7acdd64b28ee1d3d8140"><gtr:id>5b27cebc04fe7acdd64b28ee1d3d8140</gtr:id><gtr:otherNames>Tritto E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>CD1E6754724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7748EA85-BF05-4011-9F70-EF670672688C</gtr:id><gtr:title>An absence of reactive oxygen species improves the resolution of lung influenza infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e89c7491a7c08182477b643557a4377"><gtr:id>1e89c7491a7c08182477b643557a4377</gtr:id><gtr:otherNames>Snelgrove RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>8D8E8829047</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400795</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>